Context TherapeuticsCNTX
CNTX
About: Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Employees: 9
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
17% less funds holding
Funds holding: 52 [Q4 2024] → 43 (-9) [Q1 2025]
17.46% less ownership
Funds ownership: 97.06% [Q4 2024] → 79.61% (-17.46%) [Q1 2025]
43% less capital invested
Capital invested by funds: $76.4M [Q4 2024] → $43.7M (-$32.7M) [Q1 2025]
57% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 14
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
694%
upside
Avg. target
$7
1,012%
upside
High target
$9
1,330%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 1,330%upside $9 | Buy Maintained | 8 May 2025 |
HC Wainwright & Co. Emily Bodnar | 694%upside $5 | Buy Reiterated | 21 Mar 2025 |
Financial journalist opinion
Based on 3 articles about CNTX published over the past 30 days
Positive
Seeking Alpha
4 days ago
Context Therapeutics: Undervalued Cancer Fighter
Context Therapeutics offers a compelling long opportunity, with three differentiated bispecific T-cell engagers targeting solid tumors and strong early-stage clinical momentum. The company is well-capitalized, with $89 million in cash and access to additional funding, supporting operations through key Phase I data milestones into 2027. CNTX trades at a deep discount to book value and is technically oversold; positive clinical data could trigger a significant re-rating and share price upside.
Neutral
GlobeNewsWire
1 week ago
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, announced today that it is presenting a Trial in Progress poster for the Phase 1 clinical trial evaluating CTIM-76 in ovarian, endometrial, and testicular cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30 – June 3, 2025 in Chicago, IL. The Phase 1 clinical trial is an open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers.
Neutral
GlobeNewsWire
2 weeks ago
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment of Dr. Karen Chagin, M.D. as Chief Medical Officer (“CMO”), effective June 9, 2025. Dr. Chagin succeeds Dr. Karen Smith, M.D., Ph.D., MBA, LLM, who has been serving as interim CMO and will remain a member of the Company's Board of Directors (“Board”).
Neutral
GlobeNewsWire
1 month ago
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 160,000 shares of its common stock to two new employees as an inducement material for accepting employment with Context.
Neutral
GlobeNewsWire
1 month ago
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the first quarter ended March 31, 2025, and reported on recent and upcoming business highlights. Martin Lehr, CEO of Context, commented, “We continue to advance our clinical pipeline and are pleased to have two product candidates now in Phase 1 clinical trials — CTIM-76, a selective Claudin 6 (“CLDN6”) x CD3 bispecific antibody, and CT-95, a potential first-in-class mesothelin (“MSLN”) x CD3 bispecific antibody.
Neutral
GlobeNewsWire
1 month ago
Context Therapeutics Announces Chief Medical Officer Transition
Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer
Neutral
GlobeNewsWire
1 month ago
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin Data supports ongoing Phase 1 clinical trial for CT-95 PHILADELPHIA, April 30, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced preclinical and translational data regarding the Company's clinical asset, CT-95, a mesothelin x CD3 TCE was presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL. “There is a high unmet need for effective treatments in mesothelin expressing cancers.
Positive
Zacks Investment Research
1 month ago
Bet on These 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Carvana, Context Therapeutics Inc, Inovio Pharmaceuticals, ChargePoint and MSA Safety Inc.
Neutral
GlobeNewsWire
2 months ago
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context's second T cell engaging bispecific antibody to enter the clinic in 2025 PHILADELPHIA, April 09, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the first patient has been dosed in the Phase 1 clinical trial of CT-95, a mesothelin (“MSLN”) x CD3 T cell engaging (“TCE”) bispecific antibody designed to target mesothelin-expressing cancers. The Company anticipates sharing initial data for the CT-95 Phase 1 trial in mid-2026.
Positive
Zacks Investment Research
2 months ago
Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Context Therapeutics Inc. (CNTX), Blue Bird (BLBD), Dycom Industries (DY) and Leidos (LDOS).
Charts implemented using Lightweight Charts™